Peptide therapy TikTok claims: separating signal from noise

What did @murgaskinlabs actually say?

The creator pushed sermorelin as the smarter alternative to testosterone replacement therapy, especially for gay men who want body recomposition. The core pitch: sermorelin gives you the physique benefits of testosterone, "safely stimulating growth hormone," while avoiding "all these negative side effects" of TRT, including blood thickening, hair loss, and acne. The framing was essentially that sermorelin is the risk-free upgrade.

To be fair, the creator isn't wrong that sermorelin exists in a different risk category than exogenous testosterone. But the leap from "different risk profile" to "no negative side effects" is where the video starts to mislead. There's also a sleight of hand in comparing sermorelin, a growth hormone-releasing hormone (GHRH) analog, to testosterone as if they're interchangeable tools for the same job. They are not.

Does the science back this up?

Partially, but not in the way the video implies. Sermorelin stimulates the pituitary gland to release growth hormone, which is a fundamentally different mechanism than injecting exogenous testosterone. Studies do show sermorelin can improve body composition, sleep quality, and lean mass in adults with growth hormone deficiency. But the evidence base is thin compared to TRT.

A 2004 review by Sigalos and Pastuszak in the journal Therapeutic Advances in Urology notes that GHRH analogs produce more modest and slower body composition changes than testosterone in hypogonadal men. Walker and colleagues (2020, Frontiers in Endocrinology) confirmed that sermorelin's effects are highly dependent on baseline pituitary function. If your pituitary is already sluggish, sermorelin underdelivers. The claim that sermorelin will build muscle "at a quicker rate" is not supported by head-to-head comparative trials. The creator is extrapolating from GH physiology, not clinical data.

What did they get wrong (or right)?

They got the polycythemia risk right. Testosterone therapy can increase red blood cell mass, raising hematocrit and increasing cardiovascular risk. The FDA label for testosterone products includes this warning, and it is a real monitoring concern, not a scare tactic.

Where it falls apart is the "no side effects" framing. Sermorelin has documented side effects including injection site reactions, fluid retention, joint pain, and in some cases elevated fasting glucose from prolonged GH elevation. Kannan and colleagues (2011, Endocrine Practice) documented water retention and carpal tunnel symptoms in adults on GH-stimulating protocols. The creator also implies sermorelin can substitute for testosterone in men who have clinically low testosterone. It cannot. Sermorelin does not raise androgen levels. If a man has hypogonadism, sermorelin will not restore testosterone. That is a clinically significant omission, not a minor detail.

The claim that it improves "your skin, your collagen, your joints" is biologically plausible via GH and IGF-1 pathways, but is not established in controlled trials at therapeutic doses.

What should you actually know?

Sermorelin and testosterone are not competitors for the same indication. Testosterone replacement is indicated for documented hypogonadism. Sermorelin is sometimes used off-label for adults with suboptimal GH secretion, aging-related decline, or recovery support. These can overlap, but they are not the same condition or the same treatment.

The "hottest peptide" framing is a marketing posture, not a clinical one. Sermorelin has been around since the 1990s and lost FDA approval as a standalone drug in 2008, though it continues to be compounded legally under physician supervision. Anyone considering it should get baseline labs including IGF-1, testosterone, and a full metabolic panel before starting. The decision between sermorelin, testosterone, or both belongs in a conversation with a physician who has reviewed your bloodwork, not a TikTok comment section.

Framing either compound as side-effect-free to a general audience, particularly a young audience that may not have a diagnosed deficiency, creates real risk of people self-sourcing peptides without oversight.